Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beta Bionics (BBNX) EBIT Margin (2024 - 2026)

Beta Bionics' EBIT Margin history spans 3 years, with the latest figure at 87.86% for Q1 2026.

  • On a quarterly basis, EBIT Margin rose 1783.0% to 87.86% in Q1 2026 year-over-year; TTM through Mar 2026 was 70.13%, a 783.0% increase, with the full-year FY2025 number at 71.5%, down 202.0% from a year prior.
  • EBIT Margin hit 87.86% in Q1 2026 for Beta Bionics, down from 50.2% in the prior quarter.
  • Over the last five years, EBIT Margin for BBNX hit a ceiling of 50.2% in Q4 2025 and a floor of 105.69% in Q1 2025.
  • Historically, EBIT Margin has averaged 74.74% across 3 years, with a median of 73.09% in 2024.
  • Biggest five-year swings in EBIT Margin: tumbled -3259bps in 2025 and later skyrocketed 1783bps in 2026.
  • Tracing BBNX's EBIT Margin over 3 years: stood at 63.78% in 2024, then grew by 21bps to 50.2% in 2025, then tumbled by -75bps to 87.86% in 2026.
  • Business Quant data shows EBIT Margin for BBNX at 87.86% in Q1 2026, 50.2% in Q4 2025, and 62.54% in Q3 2025.